2021/2616(DEA)

Examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products

Basic information

2021/2616(DEA)

DEA - Delegated acts procedure

Supplementing 1999/0134(COD)

Subject

3.10.08 Animal health requirements, veterinary legislation and pharmacy
4.20.01 Medicine, diseases
4.20.04 Pharmaceutical products and industry
4.20.05 Health legislation and policy

Status

Procedure completed - delegated act enters into force

Key players

Key events

Date Event Reference Summary
24/03/2021 Non-legislative basic document published C(2021)01603
24/03/2021 Initial period for examining delegated act 3.0 month(s)
07/04/2021 Delegated act not objected by Council
27/04/2021 Decision by Parliament T9-0134/2021
28/04/2021 Committee referral announced in Parliament

Technical information

Procedure reference 2021/2616(DEA)
Procedure type DEA - Delegated acts procedure
Procedure subtype Examination of delegated act
Supplementing 1999/0134(COD)
Legal basis Rules of Procedure EP 0114-p6
Stage reached in procedure Procedure completed - delegated act enters into force
Committee dossier ENVI/9/05567

Documentation gateway

  • Document type Committee Reference Date Summary
    Recommendation for early non-objection of delegated act B9-0226/2021 23/04/2021
    Text adopted by Parliament, single reading T9-0134/2021 27/04/2021
  • Document type Reference Date Summary
    Non-legislative basic document C(2021)01603 24/03/2021
    Document attached to the procedure C(2021)4187 08/06/2021